Cite
HARVARD Citation
Han, M. et al. (2022). Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. pp. e351-e361. [Online].